Metabolic factors of cardiovascular risk in LIPIDOGRAM 2004 study;Wystȩpowanie metabolicznych czynników ryzyka sercowo-naczyniowego u chorych na nadciśnienie tȩtnicze i u osób z prawidłowymi wartościami ciśnienia w populacji polskiej badania LIPIDOGRAM 2004

Nadcisnienie Tetnicze

Volumn 10, Issue 5, 2006, Pages 377-391

  Szczepaniak Chicheł, Ludwina ^a   Mastej, Mirosław ^b   Piwowarska, Wiesława ^c   Jóźwiak, Jacek ^d   Konduracka, Ewa ^c   Tykarski, Andrzej ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Schwarz Pharma Sp z oo ^*

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d la skie Laboratoria Analityczne Sp z oo   (Poland)

Author keywords

Arterial hypertension; Coincidence; Metabolic risk factors

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; OBESITY; PREVALENCE; WAIST CIRCUMFERENCE;

EID: 33750425612     PISSN: 14285851     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. McMahon S.W., Macdonald G.J., Blacket R.B. Plasma lipoprotein levels in treated and untreated hypertensive men and women. The National Heart Foundation of Australia Risk Factor Prevalence Study. Arteriosclerosis 1985; 5: 391-396.
2. Gress T.W., Nieto F.J., Shahar E. i wsp. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N. Engl. J. Med. 2000; 342: 905.
3. Neaton J.D., Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch. Intern. Med. 1992; 152: 56-64.
4. Kannel W.B. W: Hypertension. Physiopatology and treatment. Genest J. i wsp. (red.). New York. NY Mc Graw Hill; 1977: 888-910.
5. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) - JAMA 2001; 285: 2486-2497.
6. Zasady postȩpowania w nadciśnieniu tȩtniczym. Stanowisko Polskiego Towarzystwa Nadciśnienia Tȩtniczego 2003. Nadciśnienie Tȩtnicze 2003; 7: A5-A21.
7. Ezzati M., Vander Horn S., Rodgers A. i wsp. Estimates of global and regional potential health gains from reducing multiple major risk factors. Lancet 2003; 362, 26: 271-280.
8. Menotti A., Lanti M. Coronary risk factors predicting early and late coronary deaths. Heart 2003; 89: 19-24.
9. Rywik S.L., Davis C.E., Paja̧k A. i wsp. Poland and US collaborative study on cardiovascular epidemiology hypertension in the community: prevalence, awareness, treatment and control of hypertension in the Pol-Monica Projectand the US Atherosclerosis Risk in Communities Study. Ann. Epidemiol. 1998; 8: 3-13.
10. Program NATPOL PLUS. Katedra Nadciśnienia Tȩtniczego i Diabetologii Akademi Medyczne w Gdańsku. Gdańsk 2003. www.natpol.pl.
11. Tendera M., Kozakiewicz K., Bartnik M. i wsp. Wystȩpowanie głównych czynników ryzyka choroby niedokrwiennej serca w grupie 41927 osób objȩtych akcja̧ prewencji pierwotnej w Polsce południowej (Southern Poland Epidemiological Survey - SPES). Wiad. Lek. 2001; 53: 292-303.
12. Zdrojewski T., Bandosz P., Szpakowski P. i wsp. Ocena wybranych problemów dotycza̧cych rozpowszechnienia i terapii nadciśnienia tȩtniczego w Polsce na podstawie badania NATPOL PLUS. W: Postȩpy w nefrologii i nadciśnieniu tȩtniczym. T. 2.2002. Wiȩcek A., Kokot F. (red.). Medycyna Praktyczna, Kraków 2003.
13. Zdrojewski T., Wyrzykowski B. NATPOL PLUS-Nadciśnienie tȩtnicze w Polsce - Zeszyt 2. Via Medica Gdańsk 2005.
14. Tykarski A., Posadzy-Małaczyńska A., Wyrzykowski B. i wsp. Rozpowszechnienie nadciśnienia tȩtniczego oraz skuteczność jego leczenia u dorosłych mieszkań ców naszego kraju. Wyniki programu WOBASZ. Kardiol. Pol. 2005; 63: 6(S4).
15. Wolf-Maier K., Cooper R.S., Bangeas J.R. i wsp. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and United States. JAMA 2003; 289: 2363-2369.
16. Kearney P.M., Whelton M., Reynolds K. i wsp. Worldwide prevalence of hypertension: a systematic review. J. Hypertens. 2004; 22: 11-19.
17. Boersma E., Keil U., De Bacquer D. i wsp. Blood pressure is insufficiently controlled in european patients with established coronary heart disease J. Hypertens. 2003; 21: 1831-1840.
18. Dongfeng Gu, Anjali Gupta, Muntner P. i wsp. Prevalence and cardiovascular disease risk factor clustering among the adult population of China results from The International Collaborative Study of Cardiovascular Disease In Asia. Circulation 2005; 112: 658-665.
19. Kannel W.B. Risk stratification in hypertension: new insights from the Framingham Study. Am. J. Hypertens. 2000; 13 (1 cz. 2): 3S-10S.
20. Stamler R., Stamler J., Riedlinger W.F. Weight and blood pressure. Findings in hypertension screening of 1 million Americans. JAMA 1978; 6; 240: 1607-1610.
21. World Health Organization. Obesity: Preventing and managing the global epidemic. Report of a WHO consultation WHO Technical Report Series, 894. Geneva, Switzerland: World Health Organization, 2000.
22. Lakka H.M., Lakka T.A., Tuomilehto J. i wsp. Abdominal obesity is associated with increased risk of acute coronary events in men. Eur. Heart J. 2002; 23, 9: 706-713.
23. Wilson P.W.F., D'Agostino R.B., Sullivan L. i wsp. Overweight and obesity as determinants of cardiovascular risk The Framingham experience. Arch. Intern. Med. 2002; 162: 1867-1872.
24. Folsom A.R., Stevens J., Schreiner P.J. i wsp. Body mass index, waist/hip ratio, and coronary heart disease incidence in African Americans and whites. Am. J. Epidemiol. 1998; 148: 1187-1194.
25. Molarius A., Seidel J.C., Sans S. i wsp. Waist and hip circumferences, and waist-hip ratio in 19 populations of the WHO MONICA Project. Int. J. Obes. 1999; 23: 116-122.
26. Rexrode K.M., Hennekens C.H., Willet W.C. i wsp. A prospective study of body mass index, weight change, and risk of stroke in women. JAMA 1997; 277: 1539-1545.
27. Siani A., Cappuccio F.P., Barba G. The relationship of waist circumference to blood pressure: the Olivetti Heart Study. Am. J. Hypertens. 2002; 15: 780-786.
28. Wolf H.K., Tuomilehto J., Kuulasmaa K. i wsp. Blood pressure levels in the 41 populations of the WHO MONICA Project. J. Hum. Hypertens. 1997; 11: 733-742.
29. McGill H.C., McMahan A., Herderick E. i wsp. Obesity accelerates the progression of coronary arteriosclerosis in young men. Circulation 2002; 105: 2712-2718.
30. Isomaa B., Almgren P., Tuomi T. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.
31. Yudkin J.S., Stehouwer C.D.A., Emeis J.J. i wsp. C-reactive protein in healthy subjects: association with obesity, insulin resistance, and endothelial dysfunction. A potential role for cytokines originating from adipose tissue? Arterioscler. Thromb. Vasc. Biol. 1999; 19: 972-978.
32. Pepine C. Ischaemic heart disease in women: facts and wishful thinking. JACC 2004; 43 (10): 1727-1730.
33. Kawecka-Jaszcz K., Jankowski P., Paja̧k A. Wtórna prewencja choroby niedokrwiennej serca u kobiet. Krakowski Program Wtórnej Prewencji Choroby Niedokrwiennej Serca. Folia Cardiol. 2001; 8: D61-D67.
34. Kasiske B.L. Ma J.Z., Kalil R.S. i wsp. Effects of antihypertensive therapy on serum lipids. Ann. Intern. Med. 1995; 122: 133-141.
35. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS Study. Br. Med. J. 1999; 314: 713-720.
36. Sharma A., Pischon T., Engeli S. i wsp. Choice of drug treatment for obesity-related hypertension: where is the evidence? J. Hypertens. 2001; 19: 667-674.
37. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J. Hypertens. 2003; 21: 1983-1992.
38. Chobanian A.V., Bakris G.L., Black H.R. i wsp. The seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The JNC7 report. JAMA 2003; 289: 2560-2572.
39. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. Guidelines Committee. J. Hypertens. 2003; 21: 1011-1053.
40. Sever P.S., Dahlöf B., Poulter N.R. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre, randomised controlled trial. Lancet 2003; 361: 1149-1158.